Advertisement

Struktur und Wirkung der Inhibitoren des Angiotensin-Converting-Enzyme

  • P. Bünning
Conference paper

Zusammenfassung

Die Inhibitoren des „Angiotensin Converting Enzyme“ (ACE) haben in den letzten Jahren Einzug in die Behandlung der Hypertonie und der Herzinsuffizienz gehalten (Brunner et al. 1985a; Hodsman u. Robertson 1983; McFate Smith 1983; Packer 1985). Diese neue Klasse von Pharmaka wurde mit der Konzeption entwickelt, die Entstehung des vasokonstriktorisch wirkenden Oktapeptidhormons Angiotensin II zu unterbinden und auf diese Weise das Renin-Angiotensin-System zu blockieren (Patchett u. Cordes 1985; Petrillo u. Ondetti 1982).

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Brunner HR, Nussberger J, Waeber B (1985a) Effects of angiotensin converting enzyme inhibition: A clinical point of view. J Cardiovasc Pharm 7(Suppl 4): S73CrossRefGoogle Scholar
  2. Brunner HR, Nussberger J, Waeber B (1985b) The present molecules of converting enzyme inhibitors. J Cardiovasc Pharm 7: S2CrossRefGoogle Scholar
  3. Bünning P (1983) The catalytic mechanism of angiotensin converting enzyme. Clin and Exper Hyper [A] 5: 1263CrossRefGoogle Scholar
  4. Cushman DW, Cheung HS, Sabo EF, Ondetti MA (1977) Design of potent competitive inhibitors of angiotensin-converting enzyme. Carboxyalkanoyl and mercaptoalkanoyl amino acids. Biochemistry 16: 5484PubMedCrossRefGoogle Scholar
  5. Drummer OH, Worland PJ, Jarrott B (1983) Tissue distribution of captopril, reducible captopril conjugates and S-methylcaptopril in the rat. Biochem Pharmacol 32: 1563PubMedCrossRefGoogle Scholar
  6. Duchin KL, Singhvi SM, Willard DA, Migdalof BH, McKinstry DN (1982) Captopril kinetics. Clin Pharmacol Ther 31: 452PubMedCrossRefGoogle Scholar
  7. Hodsman GP, Robertson JIS (1983) Captopril: Five years on. Br Med J 287: 851CrossRefGoogle Scholar
  8. Hodsman GP, Zabludowski JR, Zoccali C, Fraser R, Morton JJ, Murray GD, Robertson JIS (1984) Enalapril (MK 421) and its lysine analogue (MK 521): A comparison of acute and chronic effects on blood pressure, renin-angiotensin system and sodium excretion in normal man. Br J Clin Pharmacol 17: 223Google Scholar
  9. McFate Smith W (1983) Long-term clinical experience with enalapril. In: Doyle AE, Bearn AG (eds) Hypertension and the angiotensin system. Raven, New York, p 261Google Scholar
  10. Packer M (1985) Converting-enzyme inhibition for severe chronic heart failure: Views from a sceptic. Int J Cardiol 7: 111PubMedCrossRefGoogle Scholar
  11. Patchett AA, Cordes EH (1985) The design and properties of N-carboxyalkyldipeptide inhibitors of angiotensin-converting enzyme. In: Meister A (ed) Advances in enzymology, Vol 57. John Wiley, New York, p 1Google Scholar
  12. Patchett AA, Harris E, Tristram EW et al. (1980) A new class of angiotensin-converting enzyme inhibitors. Nature 288: 280PubMedCrossRefGoogle Scholar
  13. Peach MJ (1977) Renin-angiotensin system: Biochemistry and mechanisms of action. Physiol Rev 57: 313PubMedGoogle Scholar
  14. Petrillo Jr EW, Ondetti MA (1982) Angiotensin-converting enzyme inhibitors: Medicinal chemistry and biological actions. Med Res Rev 2: 1PubMedCrossRefGoogle Scholar
  15. Scholtholt J, Schölkens B (1984) Angiotensin converting enzyme inhibitor HOE 498. Arzneimittelforsch 34 II: 1385Google Scholar
  16. Shapiro R, Riordan JF (1984a) Inhibition of angiotensin converting enzyme: Mechanism and substrate dependence. Biochemistry 23: 5225PubMedCrossRefGoogle Scholar
  17. Shapiro R, Riordan JF (1984b) Inhibition of angiotensin converting enzyme: Dependence on chloride. Biochemistry 23: 5234PubMedCrossRefGoogle Scholar
  18. Ulm EH, Hichens M, Gomez HJ et al. (1982) Enalapril maleate and a lysine analogue (MK 521): Disposition in man. Br J Clin Pharmacol 14: 357PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1986

Authors and Affiliations

  • P. Bünning
    • 1
  1. 1.Biochemisches Institut der UniversitätFreiburg i. Br.Germany

Personalised recommendations